LizarBio Therapeutics
Dover
About LizarBio Therapeutics
LizarBio Therapeutics is developing the first of its kind plataform to produce any cell type in the body at industrial scale (>100L). By reimagining cell culture media from the ground up, we have developed negligible-cost media to cultivate and differentiate pluripotent stem cells for therapeutic applications. Currently, we are developing two cellulat therapies focused on two key areas, namely: cardiology and neurology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.7M
- Funding stage: Seed
- Last round: Seed (Mar 2022)
- Website: lizar.bio
- Phone: 8459037751
Industries & Categories
Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/lizarbio-therapeutics-92543 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.